スペインの癌診断(検査)市場

◆英語タイトル:New Frontiers in the Spanish Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape
◆発行会社/調査会社:Venture Planning Group
◆商品コード:VPCA8109
◆発行日:2014年5月
◆調査対象地域:スペイン
◆ページ数:※レポート概要をご参照ください。
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Local LicenseUSD6,700 ⇒換算¥757,100見積依頼/購入/質問フォーム
Global LicenseUSD14,700 ⇒換算¥1,661,100見積依頼/購入/質問フォーム
DataPackUSD4,350 ⇒換算¥491,550見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVenture Planning Group社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
Venture Planning Group社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[スペインの癌診断(検査)市場]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Complete report $6,700.  DataPack (test volumes, sales forecasts, supplier shares) $4,350.

“New Frontiers in the Spanish Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group’s new study of the major business opportunities emerging in the Spanish cancer diagnostics market during the next five years.  The report examines trends in the Spanish cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.  During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.  Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.  The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Spain Market Overview

- Five-year test volume and sales projections.

- Comprehensive market segmentation analysis, including review
of the market dynamics, structure, size, growth and major suppliers.

- Estimated universe of laboratories performing cancer diagnostic testing.

- Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially
significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,
Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,
Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar,
Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,
Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein,
Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,
Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product
suppliers by individual test.

- Five-year test volume and sales forecasts
for major tumor markers by market segment, including:

- Hospitals
- Commercial/Private Laboratories

Instrumentation Review

- Analysis of major molecular diagnostic and immunodignostic analyzers
used for cancer testing, including their operating characteristics,
features and selling prices.

Technology Assessment

- Assessment of latest molecular diagnostic methods,
biochips/microarrays, biosensors, monoclonal antibodies, immunoassays,
chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies
and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including
CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of companies, universities
and research centers developing new cancer diagnostic tests
and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers
and start-up firms developing innovative
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative
arrangements, and new products in R&D.

- The companies analyzed in the report include 

   - Abbott
   – AdnaGen
   – Agilent Technologies
   – Applied Gene Technologies
   – Arca/Nuvelo
   – Beckman Coulter/Danaher
   – Becton Dickinson
   – Biomedical Diagnostics
   – bioMerieux
   – Bio-Rad
   – CellSearch
   – Cepheid
   – Correlogic Systems/Vermillion
   – Decode
   – Diadexus
   – Diagnocure
   – DiaSorin
   – Eiken Chemical
   – Epigenomics
   – Enterix
   – Enzo Biochem
   – Exact Sciences
   – Fujirebio/Innogenetics
   – Guided Therapeutics
   – Hologic/Gen-Probe
   – Kreatech
   – Kyowa Medex
   – Mackay Life Sciences
   – Myriad Genetics
   – Nanogen Elitech
   – OncoLab
   – Ortho-Clinical Diagnostics
   – Panacea Pharmaceuticals
   – Polartechnics
   – Polymedco
   – PreMD
   – Qiagen/Ipsogen
   – Quest Diagnostics
   – Radient Pharmaceuticals
   – Roche
   – Scienion
   – Sequenom
   – Siemens Healthcare
   – Takara Bio
   – Targeted Diagnostics & Therapeutics
   – Thermo Fisher/Life Technologies
   – Tosoh
   – Veridex
   – Wako Pure Chemicals
   – Wallac/PE
   – Zilla

Contains 565 pages and 85 tables

*** レポート目次(コンテンツ)***

※目次は下記のURLでご確認ください。

http://www.vpgcorp.com/webfiles/CANCER/TOCLOTNewFrontiersintheSpanishCancerDiagnosticsMarketBusinessChallengesEmergingTechCompetitiveLandscape.pdf



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(VPCA8109 )"スペインの癌診断(検査)市場" (英文:New Frontiers in the Spanish Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape )はVenture Planning Group社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。